Relay Therapeutics (RLAY) Retained Earnings (2019 - 2026)

Relay Therapeutics (RLAY) has reported Retained Earnings for 8 consecutive years, with -$2.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 5526415.79% year-over-year to -$2.1 billion; the TTM figure through Mar 2026 stood at -$2.1 billion (down 5526415.79% YoY), while the FY2025 annual figure was $2.6 billion, up 248.48% from the prior year.
• Retained Earnings retreated to -$2.1 billion in Q1 2026 per RLAY's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $2.6 billion in Q4 2025 and bottomed at -$2.1 billion in Q1 2026.
• Historically, Retained Earnings has averaged $124.1 million across 5 years, with a median of -$9.2 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 185681.43% — and 2026, when it slumped 5526415.79%.
• Relay Therapeutics' Retained Earnings stood at $2.0 billion in 2022, then plunged by 100.01% to -$196000.0 in 2023, then plunged by 886782.65% to -$1.7 billion in 2024, then surged by 248.48% to $2.6 billion in 2025, then sank by 181.37% to -$2.1 billion in 2026.
• Business Quant data shows RLAY's Retained Earnings at -$2.1 billion in Q1 2026, $2.6 billion in Q4 2025, and -$2.0 billion in Q3 2025.